- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.S6289
| Related Targets | Integrase Bacterial Antibiotics Anti-infection Fungal COVID-19 Parasite Reverse Transcriptase HIV HCV Protease |
|---|---|
| Other Antiviral Inhibitors | Moroxydine HCl Aloperine GS-441524 Oleanolic Acid NGI-1 Lapachol Saikosaponin B2 Harringtonine U18666A Carrageenan |
|
In vitro |
Water : 100 mg/mL
DMSO
: Insoluble
Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 1390.71 | Formula | C60H123N15O21 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 1403-66-3 | -- | Storage of Stock Solutions |
|
|
| References |
|---|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06387147 | Not yet recruiting | Acute Mesenteric Ischemia |
Assistance Publique - Hôpitaux de Paris |
September 1 2024 | Phase 3 |
| NCT06362447 | Not yet recruiting | Ichthyosis |
University Hospital Toulouse |
April 23 2024 | Phase 2 |
| NCT05593601 | Recruiting | Colonization Asymptomatic |
Mahidol University |
November 24 2022 | Phase 4 |
| NCT05503147 | Recruiting | Malnutrition|Anorexia|Cannabis|Aging|Emergency Service Hospital|Renal Function|Pharmacokinetics |
Ove Andersen|University Hospital Bispebjerg and Frederiksberg|North Denmark Regional Hospital|University of Copenhagen|Region Hovedstadens Apotek|Glostrup University Hospital Copenhagen|Hvidovre University Hospital |
March 24 2022 | Phase 1 |
| NCT05251584 | Unknown status | Peritoneal Dialysis-related Infection |
Phramongkutklao College of Medicine and Hospital|Silpakorn University |
December 1 2021 | Not Applicable |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.